582 related articles for article (PubMed ID: 17018257)
1. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
Dessalew N; Patel DS; Bharatam PV
J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3β inhibitors.
Akhtar M; Bharatam PV
Chem Biol Drug Des; 2012 Apr; 79(4):560-71. PubMed ID: 22168279
[TBL] [Abstract][Full Text] [Related]
3. Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies.
Patel DS; Bharatam PV
Eur J Med Chem; 2008 May; 43(5):949-57. PubMed ID: 17707953
[TBL] [Abstract][Full Text] [Related]
4. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.
He Q; Han C; Li G; Guo H; Wang Y; Hu Y; Lin Z; Wang Y
Comput Biol Chem; 2020 Oct; 88():107328. PubMed ID: 32688011
[TBL] [Abstract][Full Text] [Related]
5. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
Xiao J; Guo Z; Guo Y; Chu F; Sun P
Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
[TBL] [Abstract][Full Text] [Related]
7. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR and docking studies of selective GSK-3beta inhibitors. Comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3beta ligands.
Lescot E; Bureau R; Sopkova-de Oliveira Santos J; Rochais C; Lisowski V; Lancelot JC; Rault S
J Chem Inf Model; 2005; 45(3):708-15. PubMed ID: 15921460
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
[TBL] [Abstract][Full Text] [Related]
10. In silico approaches to develop new phenyl-pyrimidines as glycogen synthase kinase 3 (GSK-3) inhibitors with halogen-bonding capabilities: 3D-QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies.
Cabezas D; Mellado G; Espinoza N; Gárate JA; Morales C; Castro-Alvarez A; Matos MJ; Mellado M; Mella J
J Biomol Struct Dyn; 2023; 41(22):13250-13259. PubMed ID: 36718094
[TBL] [Abstract][Full Text] [Related]
11. QSAR, docking, and CoMFA studies of GSK3 inhibitors.
García I; Fall Y; Gómez G
Curr Pharm Des; 2010; 16(24):2666-75. PubMed ID: 20642432
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
13. Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors.
Dowlati Beirami A; Hajimahdi Z; Zarghi A
J Biomol Struct Dyn; 2019 Jul; 37(11):2999-3006. PubMed ID: 30035675
[TBL] [Abstract][Full Text] [Related]
14. 3D QSAR pharmacophore, CoMFA and CoMSIA based design and docking studies on phenyl alkyl ketones as inhibitors of phosphodiesterase 4.
Gaurav A; Singh R
Med Chem; 2012 Sep; 8(5):894-912. PubMed ID: 22741782
[TBL] [Abstract][Full Text] [Related]
15. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
16. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking, 3D QSAR and dynamics simulation studies of imidazo-pyrrolopyridines as janus kinase 1 (JAK 1) inhibitors.
Itteboina R; Ballu S; Sivan SK; Manga V
Comput Biol Chem; 2016 Oct; 64():33-46. PubMed ID: 27244086
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods.
Pourbasheer E; Aalizadeh R
SAR QSAR Environ Res; 2016 May; 27(5):385-407. PubMed ID: 27228480
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking.
Prasanna S; Daga PR; Xie A; Doerksen RJ
J Comput Aided Mol Des; 2009 Feb; 23(2):113-27. PubMed ID: 18839067
[TBL] [Abstract][Full Text] [Related]
20. 3D QSAR studies on GSK-3 inhibition by aloisines.
Zeng M; Jiang Y; Zhang B; Zheng K; Zhang N; Yu Q
Bioorg Med Chem Lett; 2005 Jan; 15(2):395-9. PubMed ID: 15603961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
